Clinical Efficacy of Ustekinumab in Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-27

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease

NCT05705856

Crohn Disease

UNKNOWN

The Clinical Efficacy and Influence Factors of Individualized Treatment of Ustekinumab in Crohn's Disease

NCT06785493

IBD (Inflammatory Bowel Disease)

COMPLETED

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT04673357

Crohn Disease

COMPLETED PHASE3

Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases

NCT03606499

Crohn Disease Colitis, Ulcerative

COMPLETED

Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease

NCT05387031

Crohn Disease Stricture; Bowel Intestinal Stricture

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years and older;
* Patients who were first prescribed Ustekinumab between January 1 and December 31, 2024
* Patients who provided written informed consent to participate in the study

Exclusion Criteria

* Contraindications to the use of the drug Ustekinumab per the current instructions:

* Clinically significant active infection (active tuberculosis, active viral hepatitis);
* Pregnancy and lactation;
* A history of clinically significant, in the opinion of the investigator, psychiatric disorders that may interfere with the study procedures and compliance with the drug regimen;
* Ulcerative colitis;
* Malignant gastrointestinal diseases in history or at the time of inclusion in the study;
* Decompensated chronic diseases of the liver, kidneys, cardiovascular system, systemic vasculitis, diabetes mellitus;
* Abuse of alcohol or psychoactive drugs within 1 year before the start of this study (as reported by the patient);
* Participation in an interventional clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No